| Rank |
Title |
Journal |
Year |
PubWeight™‹?› |
|
1
|
A controlled trial of a critical pathway for treatment of community-acquired pneumonia. CAPITAL Study Investigators. Community-Acquired Pneumonia Intervention Trial Assessing Levofloxacin.
|
JAMA
|
2000
|
3.97
|
|
2
|
Erythropoietin with iron supplementation to prevent allogeneic blood transfusion in total hip joint arthroplasty. A randomized, controlled trial.
|
Ann Intern Med
|
2000
|
1.82
|
|
3
|
Effect of hemoglobin levels in hemodialysis patients with asymptomatic cardiomyopathy.
|
Kidney Int
|
2000
|
1.48
|
|
4
|
Differential ligand binding specificities of recombinant CD11b/CD18 integrin I-domain.
|
J Biol Chem
|
1994
|
1.18
|
|
5
|
In vitro differentiation of B lymphocytes from pre-B cells.
|
J Immunol
|
1979
|
1.09
|
|
6
|
Reduced thymic maturation but normal effector function of CD8+ T cells in CD8 beta gene-targeted mice.
|
J Exp Med
|
1994
|
1.07
|
|
7
|
Impaired immune responses toward alloantigens and tumor cells but normal thymic selection in mice deficient in the beta2 integrin leukocyte function-associated antigen-1.
|
J Immunol
|
1996
|
1.06
|
|
8
|
Functional effects of thymopoietin32-36 (TP5) on cytotoxic lymphocyte precursor units (CLP-U). I. Enhancement of splenic CLP-U in vitro and in vivo after suboptimal antigenic stimulation.
|
J Immunol
|
1980
|
1.04
|
|
9
|
A mutant human T-cell line producing immunosuppressive factor(s).
|
Cell Immunol
|
1984
|
1.02
|
|
10
|
Recombinant human platelet-derived growth factor-BB (becaplermin) for healing chronic lower extremity diabetic ulcers: an open-label clinical evaluation of efficacy.
|
Wound Repair Regen
|
2000
|
1.01
|
|
11
|
Transfusion practice in elective orthopaedic surgery.
|
Transfus Med
|
2001
|
1.00
|
|
12
|
Mechanism of action of a suppressor-activating factor (SAF) produced by a human T cell line.
|
J Immunol
|
1985
|
1.00
|
|
13
|
Treatment and outcomes of community-acquired pneumonia at Canadian hospitals.
|
CMAJ
|
2000
|
1.00
|
|
14
|
Thermoelectric magnetohydrodynamic stirring of liquid metals.
|
Phys Rev Lett
|
2010
|
0.96
|
|
15
|
Transgenic mice expressing the human high-affinity immunoglobulin (Ig) E receptor alpha chain respond to human IgE in mast cell degranulation and in allergic reactions.
|
J Exp Med
|
1996
|
0.93
|
|
16
|
Comparison of N-(4-hydroxyphenyl)retinamide and all-trans-retinoic acid in the regulation of retinoid receptor-mediated gene expression in human breast cancer cell lines.
|
Cancer Res
|
1996
|
0.91
|
|
17
|
Epoetin alfa therapy increases hemoglobin levels and improves quality of life in patients with cancer-related anemia who are not receiving chemotherapy and patients with anemia who are receiving chemotherapy.
|
J Clin Oncol
|
2001
|
0.88
|
|
18
|
Effects of tepoxalin, a dual inhibitor of cyclooxygenase/5-lipoxygenase, on events associated with NSAID-induced gastrointestinal inflammation.
|
Prostaglandins Leukot Essent Fatty Acids
|
1997
|
0.85
|
|
19
|
Tepoxalin blocks neutrophil migration into cutaneous inflammatory sites by inhibiting Mac-1 and E-selectin expression.
|
Eur J Immunol
|
1996
|
0.83
|
|
20
|
Characterization of the gene for the human high affinity IgE receptor (Fc epsilon RI) alpha-chain.
|
J Immunol
|
1993
|
0.83
|
|
21
|
In vivo enhancement of murine natural killer cell activity by 7-allyl-8-oxoguanosine (loxoribine).
|
Int J Immunopharmacol
|
1992
|
0.82
|
|
22
|
Suppression of NF kappa B activation and NF kappa B-dependent gene expression by tepoxalin, a dual inhibitor of cyclooxygenase and 5-lipoxygenase.
|
J Cell Biochem
|
1995
|
0.82
|
|
23
|
Investigating spiritual care perceptions and practice patterns in Hong Kong nurses: results of a cluster analysis.
|
Nurse Educ Today
|
2005
|
0.81
|
|
24
|
Tepoxalin enhances the activity of an antioxidant, pyrrolidine dithiocarbamate, in attenuating tumor necrosis factor alpha-induced apoptosis in WEHI 164 cells.
|
J Pharmacol Exp Ther
|
1999
|
0.81
|
|
25
|
Graft-versus-host disease in murine bone marrow transplantation. II. Modulation of acute and chronic GVHD in mice receiving bone marrow allografts pretreated with immunosuppressive factor derived from a human T cell line.
|
Immunol Lett
|
1985
|
0.80
|
|
26
|
Prior red blood cell transfusions in cancer patients increase the risk of subsequent transfusions with or without recombinant human erythropoietin management.
|
Oncologist
|
2005
|
0.80
|
|
27
|
In vivo activation of natural killer cells and priming of IL-2 responsive cytolytic cells by loxoribine (7-allyl-8-oxoguanosine).
|
Cell Immunol
|
1993
|
0.80
|
|
28
|
Effect of thymopoietin pentapeptide (TP5) on autoimmunity. I. TP5 suppression of induced erythrocyte autoantibodies in C3H mice.
|
J Immunol
|
1980
|
0.80
|
|
29
|
Studies of thymopoietin pentapeptide (TP5) on experimental tumors. I. TP5 relieves immunosuppression in tumor-bearing mice.
|
Cell Immunol
|
1982
|
0.79
|
|
30
|
The NF-kappa B inhibitor, tepoxalin, suppresses surface expression of the cell adhesion molecules CD62E, CD11b/CD18 and CD106.
|
Immunol Lett
|
1996
|
0.79
|
|
31
|
A leukocyte lipid up-regulates the avidity of lymphocyte function-associated antigen-1.
|
Biochem Biophys Res Commun
|
1994
|
0.79
|
|
32
|
Predictors of symptom resolution in patients with community-acquired pneumonia.
|
Clin Infect Dis
|
2000
|
0.78
|
|
33
|
Efficacy and safety of oral levofloxacin compared with clarithromycin in the treatment of acute sinusitis in adults: a multicentre, double-blind, randomized study. The Canadian Sinusitis Study Group.
|
J Int Med Res
|
1998
|
0.78
|
|
34
|
Tepoxalin, a novel immunomodulatory compound, synergizes with CsA in suppression of graft-versus-host reaction and allogeneic skin graft rejection.
|
Transplantation
|
1995
|
0.77
|
|
35
|
Novel thiazole based heterocycles as inhibitors of LFA-1/ICAM-1 mediated cell adhesion.
|
J Med Chem
|
1995
|
0.77
|
|
36
|
Role of aldehyde dehydrogenase in the biological activity of spermine dialdehyde, a novel immunosuppressive/purging agent.
|
Pharmacol Res
|
1992
|
0.77
|
|
37
|
Intestinal T cells in CD8 alpha knockout mice and T cell receptor transgenic mice.
|
Adv Exp Med Biol
|
1995
|
0.77
|
|
38
|
Escherichia coli Co(II) alkaline phosphatase. Absorption, circular dichroism, and magnetic circular dichroism of the d-d electronic transitions.
|
J Biol Chem
|
1973
|
0.77
|
|
39
|
Turning down the heat: new routes to inhibition of inflammatory signaling by prostaglandin H2 synthases.
|
Chem Biol
|
1995
|
0.77
|
|
40
|
Loxoribine (7-allyl-8-oxoguanosine) activates natural killer cells and primes cytolytic precursor cells for activation by IL-2.
|
J Immunol
|
1993
|
0.76
|
|
41
|
An unusual case of multiple carboxylase deficiency presenting as generalized pustular psoriasis in a Chinese boy.
|
J Inherit Metab Dis
|
1997
|
0.75
|
|
42
|
Immunoregulation by thymopoietin.
|
J Supramol Struct
|
1980
|
0.75
|
|
43
|
Lymphocytotoxins in vasculitis. Correlation with clinical manifestations and laboratory variables.
|
J Rheumatol
|
1986
|
0.75
|
|
44
|
Cytokine-modulating activity of tepoxalin, a new potential antirheumatic.
|
Int J Immunopharmacol
|
1995
|
0.75
|
|
45
|
Use of quantitative polymerase chain reaction to study cellular retinoic acid-binding protein-II mRNA expression in human skin.
|
Methods Enzymol
|
1997
|
0.75
|
|
46
|
Use of a human skin-grafted nude mouse model for the evaluation of topical retinoic acid treatment.
|
J Invest Dermatol
|
1994
|
0.75
|
|
47
|
Tepoxalin, a novel dual inhibitor of the prostaglandin-H synthase cyclooxygenase and peroxidase activities.
|
J Biol Chem
|
1995
|
0.75
|
|
48
|
Evaluation of epoetin alpha (rHuEPO) and darbepoetin alpha (DARB) on human burst-colony formation (BFU-E) in culture.
|
J Int Med Res
|
2006
|
0.75
|
|
49
|
Tepoxalin, a novel immunosuppressive agent with a different mechanism of action from cyclosporin A.
|
J Immunol
|
1994
|
0.75
|